Search Results 1521-1530 of 17021 for monoclonal antibody

1. Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) - Mayo Clinic

   Patients positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA. Cytomegalovirus (CMV) infection. Patients who are CMV PCR ...

2. A Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients with Enteric Hyperoxaluria - Mayo Clinic

   ... antibody positivity are not excluded, provided that the hepatitis B surface antigen is negative). Hepatitis C antibody positivity, unless a hepatitis C ...

3. Clinical trials - Oncology (Medical)

   This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

4. Clinical trials - Oncology (Medical)

   This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

5. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before first dose of study treatment ...

6. Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) - Mayo Clinic

   ... antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways); Has untreated central ...

7. A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer - Mayo Clinic

   Prior therapy with any of the following: PD-1, PD-L1, CTLA4 antibody, or any other drug targeting T cell checkpoint pathways. ... antibodies or infused ...

8. SC16LD6.5 in Recurrent Small Cell Lung Cancer - Mayo Clinic

   5 will be assessed by measuring the extent of tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a protein that appears ...

9. GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma - Mayo Clinic

   Due to rituximab's black box warning for Hepatitis B reactivation, patients with positive hepatitis B core antibody (anti-HBc) should have prophylactic ...

10. Blood and Marrow Transplant Research Program

    Immunoglobulin light chain (AL) amyloidosis and POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder, and ...